HK1208250A1 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments - Google Patents

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Info

Publication number
HK1208250A1
HK1208250A1 HK15108958.6A HK15108958A HK1208250A1 HK 1208250 A1 HK1208250 A1 HK 1208250A1 HK 15108958 A HK15108958 A HK 15108958A HK 1208250 A1 HK1208250 A1 HK 1208250A1
Authority
HK
Hong Kong
Prior art keywords
cancer
growth factor
factor receptor
epidermal growth
receptor targeting
Prior art date
Application number
HK15108958.6A
Other languages
English (en)
Chinese (zh)
Inventor
Daphne Winifred Bell
Daniel A Haber
Pasi Antero Janne
Bruce E Johnson
Thomas J Lynch
Matthew Meyerson
Juan Guillermo Paez
William R Sellers
Jeffrey E Settleman
Raffaella Sordella
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HK1208250A1 publication Critical patent/HK1208250A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
HK15108958.6A 2004-03-31 2015-09-14 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments HK1208250A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US55821804P 2004-03-31 2004-03-31
US56109504P 2004-04-09 2004-04-09
US56598504P 2004-04-27 2004-04-27
US56575304P 2004-04-27 2004-04-27
US57403504P 2004-05-25 2004-05-25
US57791604P 2004-06-07 2004-06-07
US59228704P 2004-07-29 2004-07-29

Publications (1)

Publication Number Publication Date
HK1208250A1 true HK1208250A1 (en) 2016-02-26

Family

ID=35064318

Family Applications (4)

Application Number Title Priority Date Filing Date
HK15108958.6A HK1208250A1 (en) 2004-03-31 2015-09-14 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK16100376.6A HK1212397A1 (en) 2004-03-31 2016-01-14 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK18111696.4A HK1252399A1 (zh) 2004-03-31 2018-09-12 測定癌症對表皮生長因子受體靶向性治療反應性的方法
HK18114005.4A HK1254906A1 (zh) 2004-03-31 2018-11-02 測定癌症對表皮生長因子受體靶向性治療反應性的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK16100376.6A HK1212397A1 (en) 2004-03-31 2016-01-14 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK18111696.4A HK1252399A1 (zh) 2004-03-31 2018-09-12 測定癌症對表皮生長因子受體靶向性治療反應性的方法
HK18114005.4A HK1254906A1 (zh) 2004-03-31 2018-11-02 測定癌症對表皮生長因子受體靶向性治療反應性的方法

Country Status (14)

Country Link
US (8) US7294468B2 (fr)
EP (6) EP2439285B1 (fr)
JP (6) JP4350148B2 (fr)
KR (3) KR101347613B1 (fr)
CN (6) CN104774931B (fr)
AU (4) AU2005228446B2 (fr)
BR (1) BRPI0508286B8 (fr)
CA (1) CA2556227C (fr)
DK (5) DK1733056T3 (fr)
ES (5) ES2741547T3 (fr)
HK (4) HK1208250A1 (fr)
PT (1) PT1733056E (fr)
SI (1) SI1733056T1 (fr)
WO (1) WO2005094357A2 (fr)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
CA2447139C (fr) 2001-05-11 2013-11-19 Ludwig Institute For Cancer Research Proteines de liaison specifiques et utilisations associees
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
WO2005118876A2 (fr) * 2004-06-04 2005-12-15 Genentech, Inc. Mutations de egfr
TW200617396A (en) * 2004-10-06 2006-06-01 Astrazeneca Ab Method
ES2359322T3 (es) * 2004-10-18 2011-05-20 Brandeis University Procedimiento para la amplificación de ácidos nucleicos.
WO2006070667A1 (fr) * 2004-12-28 2006-07-06 Takara Bio Inc. Procede de detection d'une mutation dans le gene egfr et kit de detection
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
WO2006091899A2 (fr) 2005-02-24 2006-08-31 Amgen Inc. Mutations de recepteur de facteur de croissance epidermique
GB0506670D0 (en) * 2005-04-01 2005-05-11 Astrazeneca Ab Method
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
EP1874920A4 (fr) 2005-04-05 2009-11-04 Cellpoint Diagnostics Dispositifs et procédés permettant d'enrichir et de modifier des cellules tumorales circulantes et d'autres particules
KR20080002826A (ko) * 2005-04-14 2008-01-04 와이어쓰 게피티니브 내성 환자에서의 표피 성장 인자 수용체（ｅｇｆｒ） 키나제 억제제의 용도
CA2612183C (fr) * 2005-06-28 2015-08-11 Genentech, Inc. Mutations chez r-egf et kras
CA2624613A1 (fr) * 2005-10-05 2007-04-12 Astrazeneca Uk Limited Methode pour predire ou surveiller la reponse d'un patient a un medicament de recepteur erbb
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
EP3173084B1 (fr) * 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Dérivés de quinazoline pour le traitement de cancers
DK1948180T3 (da) * 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
WO2007099852A1 (fr) * 2006-02-23 2007-09-07 National University Corporation Kanazawa University Procédé destiné à tester la sensibilité d'un cancer solide contre un inhibiteur de tyrosine kinase et nécessaire de test correspondant
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
ES2394224T3 (es) 2006-05-05 2013-01-23 Yale University Uso de perfiles de localización subcelular como indicadores de prognóstico o predictivos
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) * 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
EP3424598B1 (fr) 2006-06-14 2022-06-08 Verinata Health, Inc. Analyse de cellules rares utilisant la division d'échantillons et les marqueurs d'adn
WO2008008500A2 (fr) * 2006-07-13 2008-01-17 Yale University Procédés pronostiques du cancer à partir de la localisation subcellulaire de biomarqueurs
ES2385613T3 (es) * 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
WO2008038812A1 (fr) * 2006-09-28 2008-04-03 Shimadzu Corporation Procédé permettant de préparer un échantillon pour la spectrométrie de masse à désorption-ionisation laser assistée par matrice et procédé de spectrométrie de masse à désorption-ionisation laser assistée par matrice
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CA2680326A1 (fr) 2007-03-13 2008-09-18 Amgen Inc. Mutations de kras et traitement avec des anticorps anti-egfr
WO2008112274A2 (fr) * 2007-03-13 2008-09-18 Amgen Inc. Mutations de k-ras et de b-raf et thérapie utilisant des anticorps anti-egfr
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8999634B2 (en) 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
US8268793B2 (en) 2007-05-11 2012-09-18 Santaris Pharma A/S RNA antagonist compounds for the modulation of HER3
WO2009005715A1 (fr) * 2007-06-29 2009-01-08 Yale University Procédés d'essai diagnostic prédictif du tamoxifène
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SG10201609507TA (en) 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
PT2271767T (pt) * 2008-04-03 2016-08-18 Cb Biotechnologies Inc Reação em cadeia de polimerase para captura de amplicões em multiplexo para amplificação de alvos múltiplos
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
CN101445829B (zh) * 2008-04-23 2013-06-05 广州益善生物技术有限公司 Egfr基因突变位点的检测探针、液相芯片及其检测方法
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
BRPI0917871A2 (pt) * 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
US12090480B2 (en) 2008-09-23 2024-09-17 Bio-Rad Laboratories, Inc. Partition-based method of analysis
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
WO2011120020A1 (fr) 2010-03-25 2011-09-29 Quantalife, Inc. Système de transport de gouttelettes à des fins de détection
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
EP3075864A1 (fr) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gène et protéine exprimées par des gènes cibles représentant des profils de biomarqueurs et ensembles de signature par type de tumeurs
WO2010093465A1 (fr) * 2009-02-11 2010-08-19 Caris Mpi, Inc. Profil moléculaire de tumeurs
GB2480980A (en) * 2009-03-02 2011-12-07 Trackfive Diagnostics Inc Methods for predicting cancer response to EGFR inhibitors
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
CA2767056C (fr) 2009-09-02 2018-12-04 Bio-Rad Laboratories, Inc. Systeme de melange de fluides par coalescence d'emulsions multiples
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
US20130005592A1 (en) * 2009-09-10 2013-01-03 Board Of Regents Of The University Of Texas System Methods and compositions for predicting cancer therapy response
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
US9034658B2 (en) 2009-11-23 2015-05-19 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
US10731221B2 (en) 2009-12-11 2020-08-04 Dignity Health Diagnosing IDH1 related subgroups and treatment of cancer
WO2011072258A1 (fr) * 2009-12-11 2011-06-16 Catholic Healthcare West Détermination de sous-groupes de cancer sur la base de voie pi3k/akt : méthode d'utilisation de biomarqueurs à des fins de diagnostic et de traitement
TWI405566B (zh) * 2010-02-11 2013-08-21 Univ Nat Taiwan 薑黃素或其類似物於使用上皮細胞生長因子接受器酪胺酸激酶抑制劑之癌症醫療之用途
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
JP2013522613A (ja) * 2010-03-18 2013-06-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 化学療法に対する応答性を予測するための方法
EP2550351A4 (fr) 2010-03-25 2014-07-09 Quantalife Inc Système de détection pour analyses à base de gouttelettes
EP2550528B1 (fr) 2010-03-25 2019-09-11 Bio-Rad Laboratories, Inc. Génération de gouttelettes pour dosages sur gouttelettes
CN102234683B (zh) * 2010-04-23 2013-07-17 广州益善生物技术有限公司 一种egfr基因突变检测液相芯片
CN101858909B (zh) * 2010-05-28 2013-07-03 广州瑞博奥生物科技有限公司 检测磷酸化表皮生长因子受体的试剂盒及其制备方法
WO2012040387A1 (fr) 2010-09-24 2012-03-29 The Board Of Trustees Of The Leland Stanford Junior University Capture directe, amplification et séquençage d'adn cible à l'aide d'amorces immobilisées
JP5996431B2 (ja) * 2010-09-30 2016-09-21 Ｌｓｉｐファンド運営合同会社 優性変異遺伝子発現抑制剤
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
CN103429331B (zh) 2010-11-01 2016-09-28 伯乐生命医学产品有限公司 用于形成乳液的系统
WO2012065071A2 (fr) * 2010-11-12 2012-05-18 The Broad Institute Of Mit And Harvard Procédés de prédiction d'une réponse à une thérapie par un anticorps anti-egfr
WO2012065705A1 (fr) 2010-11-19 2012-05-24 Roche Diagnostics Gmbh Nouvelle mutation complexe dans le domaine kinase du récepteur du facteur de croissance épidermique
US20120164641A1 (en) 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
CN102140518B (zh) * 2011-01-18 2013-02-06 杭州迪安医学检验中心有限公司 肺癌相关表皮生长因子受体egfr外显子突变定量检测试剂盒及方法
US9738930B2 (en) 2011-01-28 2017-08-22 The Broad Institute, Inc. Paired end bead amplification and high throughput sequencing
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
JP5881746B2 (ja) 2011-02-15 2016-03-09 ライカ バイオシステムズ ニューキャッスル リミテッド ｍＲＮＡの局在インサイチュー検出のための方法
US9556473B2 (en) 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
US12097495B2 (en) 2011-02-18 2024-09-24 Bio-Rad Laboratories, Inc. Methods and compositions for detecting genetic material
EP2492688A1 (fr) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Biomarqueurs moléculaires pour la prédiction de la réponse à un traitement antitumoral dans le cancer du poumon
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
WO2012129187A1 (fr) 2011-03-18 2012-09-27 Bio-Rad Laboratories, Inc. Essais numériques multiplexés avec utilisation combinée de signaux
EP2702175B1 (fr) 2011-04-25 2018-08-08 Bio-Rad Laboratories, Inc. Procédés et compositions pour l'analyse d'acide nucléique
JP5930825B2 (ja) * 2011-05-06 2016-06-08 アークレイ株式会社 Ｅｇｆｒエクソン１９多型検出試験用試薬キット及びその用途
WO2013019751A1 (fr) 2011-07-29 2013-02-07 Bio-Rad Laboratories, Inc., Caractérisation de banque par essai numérique
CA2842359A1 (fr) 2011-08-01 2013-02-07 Denovo Sciences Systeme de capture de cellules et procede d'utilisation
US9404864B2 (en) 2013-03-13 2016-08-02 Denovo Sciences, Inc. System for imaging captured cells
US10466160B2 (en) 2011-08-01 2019-11-05 Celsee Diagnostics, Inc. System and method for retrieving and analyzing particles
US9174216B2 (en) 2013-03-13 2015-11-03 DeNovo Science, Inc. System for capturing and analyzing cells
WO2013022961A1 (fr) 2011-08-08 2013-02-14 3The Broad Institute Compositions et procédés pour la co-amplification de sous-séquences d'une séquence de fragment d'acide nucléique
US9738935B2 (en) * 2011-11-10 2017-08-22 Roche Molecular Systems, Inc. Complex mutations in the epidermal growth factor receptor kinase domain
CN104066481A (zh) * 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
US9260714B2 (en) 2011-12-02 2016-02-16 Roche Molecular Systems, Inc. Suppression of non-specific amplification with high-homology oligonucleotides
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP2653558B1 (fr) 2012-04-18 2015-10-07 Roche Diagniostics GmbH Procédé de détection de cibles d'acide nucléique à l'aide d'un classificateur statistique
CN102732636B (zh) * 2012-07-17 2014-01-15 海南医学院 一种检测肿瘤细胞egfr基因突变的芯片
CN102851375B (zh) * 2012-09-11 2014-02-19 上海源奇生物医药科技有限公司 检测egfr基因突变的引物、探针及其试剂盒和使用方法
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US20140341884A1 (en) * 2012-12-04 2014-11-20 Roche Molecular Systems, Inc. Novel Complex Mutations in the Epidermal Growth Factor Receptor Kinase Domain
US9752181B2 (en) 2013-01-26 2017-09-05 Denovo Sciences, Inc. System and method for capturing and analyzing cells
MX362247B (es) 2013-03-06 2019-01-09 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.
US9873913B2 (en) 2013-03-08 2018-01-23 Roche Molecular Systems, Inc. Mutation testing
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
US9707562B2 (en) 2013-03-13 2017-07-18 Denovo Sciences, Inc. System for capturing and analyzing cells
US9856535B2 (en) 2013-05-31 2018-01-02 Denovo Sciences, Inc. System for isolating cells
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
CN103333963A (zh) * 2013-06-09 2013-10-02 中国人民解放军第四军医大学 Egfr突变检测引物组及其用途
WO2014203918A1 (fr) * 2013-06-19 2014-12-24 学校法人 久留米大学 Procédé de prédiction d'effet thérapeutique d'inhibiteurs de la tyrosine kinase du récepteur du facteur de croissance épidermique
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103923975B (zh) * 2014-01-27 2016-01-20 上海涌泰生物医药科技有限公司 一种检测egfr基因外显子19缺失突变的试剂盒和方法
WO2015178946A1 (fr) 2014-04-04 2015-11-26 Biodesix, Inc. Sélection d'un traitement pour les patients atteints d'un cancer du poumon faisant appel au spectre de masse d'un échantillon de sang
CN106573967B (zh) * 2014-07-28 2022-02-18 玛尔医学研究所基金会 表皮生长因子受体基因的胞外域iii中的突变
EP3204510B1 (fr) 2014-10-09 2018-07-25 Roche Diagnostics GmbH Nouvelles mutations complexes dans le domaine kinase du récepteur de facteur de croissance épidermique
KR101692044B1 (ko) * 2014-12-05 2017-01-04 사회복지법인 삼성생명공익재단 교모세포종에서 표피 성장인자 수용체 억제제의 치료 효과를 예측하는 방법
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW201739919A (zh) * 2016-02-12 2017-11-16 南坦生物組學有限責任公司 患者特異性新抗原決定基之高通量識別以作為用於癌症免疫療法之治療劑
CN105624309B (zh) * 2016-02-23 2020-04-21 深圳华大生命科学研究院 检测EGFR和/或K-ras基因突变的引物、探针及试剂盒
CN105866217B (zh) * 2016-03-21 2018-04-10 杭州市红十字会医院 三尖杉酯碱癌症治疗效果检测装置及方法
WO2017204577A1 (fr) * 2016-05-25 2017-11-30 주식회사 젠큐릭스 Composition pour la détection d'une mutation d'un gène du récepteur du facteur de croissance des cellules épidermiques et kit la comprenant
WO2018195339A1 (fr) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Cellules immunitaires exprimant des récepteurs d'antigènes modifiés
WO2018201584A1 (fr) * 2017-05-03 2018-11-08 华为技术有限公司 Procédé et dispositif de transmission par concurrence
US10299039B2 (en) 2017-06-02 2019-05-21 Apple Inc. Audio adaptation to room
US10391493B2 (en) 2017-08-29 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
WO2019074920A1 (fr) * 2017-10-10 2019-04-18 Oncocyte Corporation Méthodes et compositions pour la détection et le diagnostic du cancer du sein
CN109722476A (zh) * 2017-10-31 2019-05-07 北京雅康博生物科技有限公司 用于检测egfr基因2237-2257位突变的引物、探针及试剂盒
WO2019213195A1 (fr) * 2018-05-01 2019-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t reconnaissant un egfr muté
WO2020080871A2 (fr) * 2018-10-18 2020-04-23 (주)신테카바이오 Composition de biomarqueur de détermination de réactivité d'un médicament contre le cancer, méthode de détermination de réactivité d'un médicament contre le cancer à l'aide de la composition de biomarqueur, et puce de diagnostic de détection de composition de biomarqueur de détermination de réactivité d'un médicament contre le cancer
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
JP7413408B2 (ja) 2019-05-07 2024-01-15 バイオ－ラッド ラボラトリーズ インコーポレイテッド 自動化された単一細胞処理のためのシステムおよび方法
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
WO2020230091A1 (fr) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération
CA3143241A1 (fr) 2019-06-14 2020-12-17 Bio-Rad Laboratories, Inc. Systeme et procede de traitement automatique de cellules individuelles et analyses
GB2627085A (en) 2019-11-06 2024-08-14 Univ Leland Stanford Junior Methods and systems for analysing nucleic acid molecules
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
CN111154881A (zh) * 2020-03-09 2020-05-15 南京实践医学检验有限公司 一种急性髓系白血病中基因突变的检测试剂盒及应用
US11504719B2 (en) 2020-03-12 2022-11-22 Bio-Rad Laboratories, Inc. System and method for receiving and delivering a fluid for sample processing
US20220025453A1 (en) * 2020-07-23 2022-01-27 Michael Y Sha Xenonucleic acid-mediated multiplex qpcr clamping technology for lung cancer mutation detection
CN114107449B (zh) * 2020-08-31 2024-04-09 中山大学孙逸仙纪念医院 一种单细胞内原位qPCR方法
CN111996193B (zh) * 2020-09-11 2024-02-20 北京键凯科技股份有限公司 一种有效抑制表皮生长因子受体表达的siRNA序列
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
CN113564255A (zh) * 2021-08-13 2021-10-29 河北医科大学第四医院 一种lncRNA NEAT1_1的应用
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN114113265B (zh) * 2021-12-14 2023-08-08 郑州轻工业大学 一种适配体传感器及其制备方法
WO2023190967A1 (fr) * 2022-03-31 2023-10-05 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 Biomarqueur de traitement de cancer solide par dérivé d'imidazo[4,5-b]pyridine

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811A (en) 1848-09-26 Improvement in hemp-brakes
US234A (en) 1837-06-14 Improvement in machines for breaking hemp and flax
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4046784A (en) 1975-04-04 1977-09-06 Texaco Development Corporation Boride catalyst for epoxidizing olefinic compounds
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
AU639726B2 (en) * 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
ES2156859T5 (es) 1991-03-18 2008-03-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
DE4129533A1 (de) 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JPH08510250A (ja) 1993-05-17 1996-10-29 イムノメディクス，インコーポレイテッド ビオチンまたはアビジンと金属キレート化タンパク質との複合体による病変の検出および治療法の改善
US5593688A (en) 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
EP0657811B1 (fr) 1993-12-09 1998-09-02 STMicroelectronics S.r.l. Circuit intégré de contrÔle de l'utilisation des éléments de mémoire redondantes dans un dispositif de mémoire à semi-conducteurs
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
EP3103799B1 (fr) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Derives de quinazoline
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
EP0824525B1 (fr) 1995-04-27 2001-06-13 AstraZeneca AB Derives de quinazoline
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
US6015670A (en) 1996-05-17 2000-01-18 Hexagen Technology Limited Methods for identifying a mutation in a gene of interest without a phenotypic guide using ES cells
US5861251A (en) * 1996-10-15 1999-01-19 Bioneer Corporation Lyophilized reagent for polymerase chain reaction
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
WO2000004194A1 (fr) 1998-07-20 2000-01-27 Variagenics, Inc. Variance de sequences de genes pouvant etre utile pour determiner le traitement d'une maladie
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
JP2004514427A (ja) 2000-11-24 2004-05-20 パンセコ・アクティーゼルスカブ Ｐｎａ類似物
US7521175B2 (en) * 2001-06-14 2009-04-21 The Regents Of The University Of California Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
WO2005006940A2 (fr) * 2003-06-19 2005-01-27 University Of Medicine And Dentistry Of New Jersey Detection de mutations dans des sequences nucleotidiques
BRPI0413255A (pt) 2003-08-01 2006-10-03 Wyeth Corp uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
US8323987B2 (en) 2004-02-17 2012-12-04 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
WO2005118876A2 (fr) * 2004-06-04 2005-12-15 Genentech, Inc. Mutations de egfr

Also Published As

Publication number Publication date
WO2005094357A3 (fr) 2008-12-24
EP2423331A2 (fr) 2012-02-29
EP2447375A2 (fr) 2012-05-02
CN104774931B (zh) 2017-11-10
SI1733056T1 (sl) 2013-10-30
DK2439285T3 (da) 2019-07-29
CN104480200A (zh) 2015-04-01
ES2741573T3 (es) 2020-02-11
CN102586431B (zh) 2015-04-22
CN107988363A (zh) 2018-05-04
BRPI0508286B8 (pt) 2021-05-25
ES2741546T3 (es) 2020-02-11
DK2423331T3 (da) 2019-07-29
JP4468475B2 (ja) 2010-05-26
EP2423331B1 (fr) 2019-05-08
EP1733056A2 (fr) 2006-12-20
AU2005228446A1 (en) 2005-10-13
AU2012202668A1 (en) 2012-05-31
CN102586431A (zh) 2012-07-18
US20080207615A1 (en) 2008-08-28
HK1212397A1 (en) 2016-06-10
CN101501211A (zh) 2009-08-05
EP2439285A1 (fr) 2012-04-11
US20080096212A1 (en) 2008-04-24
US7294468B2 (en) 2007-11-13
JP5449943B2 (ja) 2014-03-19
CN107794302A (zh) 2018-03-13
US20150176081A1 (en) 2015-06-25
JP2010051316A (ja) 2010-03-11
US20080234264A1 (en) 2008-09-25
KR20130008075A (ko) 2013-01-21
US8465916B2 (en) 2013-06-18
CA2556227A1 (fr) 2005-10-13
AU2012202668B9 (en) 2015-02-12
JP5688399B2 (ja) 2015-03-25
KR20120087880A (ko) 2012-08-07
AU2007202288B2 (en) 2012-02-09
US9035036B2 (en) 2015-05-19
CN104774931A (zh) 2015-07-15
AU2015201692A1 (en) 2015-04-23
ES2425749T3 (es) 2013-10-17
US20130316935A1 (en) 2013-11-28
JP2017074048A (ja) 2017-04-20
JP4350148B2 (ja) 2009-10-21
KR101347613B1 (ko) 2014-01-06
AU2012202668B2 (en) 2015-02-05
JP2013059339A (ja) 2013-04-04
EP2447375A3 (fr) 2012-08-22
EP1733056A4 (fr) 2009-08-12
US10000815B2 (en) 2018-06-19
DK1733056T3 (da) 2013-08-26
HK1254906A1 (zh) 2019-08-02
US7964349B2 (en) 2011-06-21
CN104480200B (zh) 2017-12-29
JP6557646B2 (ja) 2019-08-07
AU2007202288A1 (en) 2007-06-14
EP2447375B1 (fr) 2019-05-08
AU2005228446C1 (en) 2005-10-13
DK2447375T3 (da) 2019-07-29
ES2741547T3 (es) 2020-02-11
US20060147959A1 (en) 2006-07-06
US10669589B2 (en) 2020-06-02
US8105769B2 (en) 2012-01-31
HK1252399A1 (zh) 2019-05-24
CA2556227C (fr) 2013-03-19
EP3611273A1 (fr) 2020-02-19
EP2423331A3 (fr) 2012-06-27
AU2015201692B2 (en) 2017-03-02
CN107794302B (zh) 2022-03-15
KR20070031894A (ko) 2007-03-20
EP2439285B1 (fr) 2019-05-08
EP1733056B1 (fr) 2013-05-22
BRPI0508286A (pt) 2007-07-31
JP2015023865A (ja) 2015-02-05
US20210017604A1 (en) 2021-01-21
US12006555B2 (en) 2024-06-11
DK2439284T3 (da) 2019-07-29
US20180251860A1 (en) 2018-09-06
WO2005094357A2 (fr) 2005-10-13
EP2439284B1 (fr) 2019-05-08
EP2439284A1 (fr) 2012-04-11
ES2741574T3 (es) 2020-02-11
BRPI0508286B1 (pt) 2020-12-29
JP2007531525A (ja) 2007-11-08
AU2005228446B2 (en) 2007-02-22
PT1733056E (pt) 2013-08-29
JP2009171965A (ja) 2009-08-06
KR101289774B1 (ko) 2013-08-07
KR101368446B1 (ko) 2014-02-28

Similar Documents

Publication Publication Date Title
HK1254906A1 (zh) 測定癌症對表皮生長因子受體靶向性治療反應性的方法
EP1751309A4 (fr) Methodes de prediction d'un avantage clinique relativement a des inhibiteurs du recepteur de facteur de croissance epidermique pour des cancereux
IL196077A0 (en) Appatatus and method for stimulation of biological tissue
GB0600018D0 (en) R adiation applicator and method of radiating tissue
EP1824520A4 (fr) Methodes pour detecter le cancer de la prostate
AU2003251597A8 (en) Method for predicting response to epidermal growth factor receptor-directed therapy
EP2223243A4 (fr) Procédé et système pour améliorer l'utilisation de chercheurs humains
ZA201001512B (en) Inhibitors of protein tyrosine kinase activity
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
ZA200610338B (en) Formulation for stimulating hair growth
IL197649A0 (en) System and method for tracking healing progress of tissue
EP2249827A4 (fr) Utilisation de picoplatine et de cetuximab dans le traitement du cancer colorectal
EP2224452A4 (fr) Système et procédé d'ajustement du ph
EP1991231A4 (fr) Méthodes de traitement de maladies en utilisant des inhibiteurs de nucléoside phosphorylases et de nucléosidases
EP1864134A4 (fr) Méthodes de traitement ou de prévention du cancer de la prostate hormono-résistant au moyen de petits arn interférents spécifiques de la protocadherine-pc, ou d'autres inhibiteurs de l'expression ou de l'activité de la protocadherine-pc
HRP20150007T8 (hr) Lijeäśenje tumora pomoä†u specifiäśnog anti-l1 protutijela
EP1789082A4 (fr) Vaccins cellulaires exprimant les cytokines destines au traitement du cancer de la prostate
EP2039757A4 (fr) Procédé de culture cellulaire ou tissulaire
EP1926824A4 (fr) Procede de determination de la reactivite au traitement a l'erytropoietine
IL177001A0 (en) Method for stimulating hair growth
WO2008124843A9 (fr) Utilisation combinée d'ultrasons et de facteurs de croissance pour stimuler la formation d'os
IL204632A0 (en) Epidermal stimulation to enhance hair follicle formation
GB0422634D0 (en) Method of treating skin diseases
IL181003A0 (en) Methods of treating proliferative skin diseases using carbazole derivatives
AU2004907352A0 (en) Methods of treating pain